Supernus Pharmaceuticals seeks Nasdaq delisting following merger completion
SUPN•Supernus Pharmaceuticals requested Nasdaq delisting after completing its merger on November 2, 2026, and asked for trading to be suspended before that day's market open.
1. Delisting request
Supernus asked Nasdaq to file Form 25 to delist and deregister its common stock under Section 12(b) of the Exchange Act. After Form 25 takes effect, it plans to file Form 15 to deregister the stock and suspend its Exchange Act reporting obligations; the stock will no longer trade on a national securities exchange.
